home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409a.zip
/
M9490155.TXT
< prev
next >
Wrap
Text File
|
1994-09-03
|
3KB
|
47 lines
Document 0155
DOCN M9490155
TI In vitro effects of stem-cell factor or interleukin-3 on
myelosuppression associated with AIDS.
DT 9411
AU Scadden DT; Wang A; Zsebo KM; Groopman JE; Department of Medicine, New
England Deaconess Hospital, Harvard; Medical School, Boston, MA 02215.
SO AIDS. 1994 Feb;8(2):193-6. Unique Identifier : AIDSLINE MED/94318202
AB OBJECTIVE: To determine whether the early-acting hematopoietic growth
factors stem-cell factor (SCF) or interleukin-3 (IL-3), are able to
overcome the bone-marrow suppressive effects of cytokines or drugs
involved in the hematologic abnormalities that accompany HIV-1
infection. DESIGN: In vitro colony formation assays of normal human
bone-marrow cells exposed to the myelosuppressive drugs, zidovudine,
interferon-alpha (IFN-alpha) and ganciclovir, or the myelosuppressive
cytokines, tumor necrosis factor-alpha (TNF-alpha) or transforming
growth factor-beta (TGF-beta), implicated in HIV dysmyelopoiesis.
RESULTS: SCF (10 ng/ml) enhanced the numbers of erythroid (BFU-E)
colonies in the presence of zidovudine or ganciclovir (P < 0.05) and
myeloid [colony-forming unit granulocyte macrophage (CFU-GM)] colonies
in the presence of ganciclovir or IFN-alpha (P < 0.05) relative to
controls. IL-3 (10 ng/ml) also improved erythroid colony numbers in the
presence of zidovudine (P < 0.05) and CFU-GM in the presence of
IFN-alpha (P < 0.05). Neither factor consistently altered the inhibition
of TGF-beta or TNF-alpha. The 50% inhibitory concentration (IC50) of the
myelosuppressive agents was altered in only one setting, using IL-3 in
the presence of zidovudine. CONCLUSIONS: These data suggest that SCF or
IL-3 may have a therapeutic application in overcoming hematopoietic
abnormalities associated with drugs commonly used in the care of AIDS
patients. However, they may have less capacity to overcome the
bone-marrow inhibitory effects of the endogenous cytokines TNF-alpha and
TGF-beta.
DE Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY Bone
Marrow Diseases/*CHEMICALLY INDUCED Cell Division/DRUG EFFECTS
Colony-Forming Units Assay Comparative Study Erythroid Progenitor
Cells/DRUG EFFECTS Ganciclovir/PHARMACOLOGY Granulocyte-Macrophage
Colony-Stimulating Factor/PHARMACOLOGY Granulocytes Hematopoietic Cell
Growth Factors/*PHARMACOLOGY Hematopoietic Stem Cells/*DRUG EFFECTS
Human Interferon Alfa-2a/PHARMACOLOGY Interleukin-3/*PHARMACOLOGY
Macrophages Recombinant Proteins/PHARMACOLOGY Support, U.S. Gov't,
P.H.S. Transforming Growth Factor beta/PHARMACOLOGY Tumor Necrosis
Factor/PHARMACOLOGY Zidovudine/PHARMACOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).